National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Risankizumab (Skyrizi®) HTA ID: 19010

Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 04/03/2019
Rapid review completed 22/05/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Full pharmacoeconomic assessment commissioned by HSE 28/08/2019
Pre-submission consultation with Applicant 21/07/2020
Full submission received from Applicant 12/10/2020
Preliminary review sent to Applicant 09/03/2021
NCPE assessment re-commenced 15/04/2021
Factual accuracy sent to Applicant 16/07/2021
NCPE assessment recommenced 26/07/2021
NCPE assessment completed 12/08/2021
NCPE assessment outcome The NCPE recommends that risankizumab (Skyrizi®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013